Current methods for assessing safety pharmacology in the context of cardiac arrhythmia risk are unable to distinguish between drugs that cause cardiac rhythm disturbances and benign drugs. Drugs deemed likely to be unsafe share the common property of blocking the human Ether-à-go-go-Related Gene (hERG) encoded cardiac potassium channel and consequent prolongation of QT interval on the ECG. However, hERG block and QT prolongation alone are not selective indicators for cardiac arrhythmia. Here we present a prototype computational framework to distinguish between safe and unsafe hERG blockers. We used recent cryo-EM hERG structure to build and validate an atomistic structural model of the channel open conducting state. We also developed structural atomistic models of dofetilide, a hERG blocking drug with high pro-arrhythmia risk, in both charged and neutral ionization states. Next, we employed unbiased and enhanced sampling all-atom molecular dynamics (MD) simulations to probe atomic-scale mechanisms of dofetilide interaction with openstate hERG. Multi-microsecond drug "flooding" simulations revealed spontaneous dofetilide binding to the channel pore through the intracellular gate. Umbrella sampling MD was used to compute dofetilide affinity to hERG, in good agreement with experiment, as well as ingress and egress rates, which in a novel linkage between the atomistic and functional scale are utilized in our companion paper (Yang P-C et al. 2019 bioRxiv:635433) to parameterize functional kinetic models of dofetilide -hERG interactions used to predict emergent drug effects on the cardiac rhythm. This study represents the first necessary components of a computational framework for virtual cardiac safety pharmacology screening from the atom to the rhythm.
Introduction

"Poisons and medicine are often the same substance given with different intents" wrote Peter
Mere Latham in the 19th-century (1) . Drug binding to a receptor protein is determined by the chemical composition of the drug and its interaction with the local protein environment (2) . Even slight modification to drug chemistry may impact the potency of binding, and the resulting functional impact can vary widely from therapeutic to lethal (3) . Although these principles are well understood (4) , it has been an exceedingly difficult problem to predict the link between drug chemistry and altered physiological function. A persistent example of drug failure that cannot be predicted from drug chemical composition is unanticipated cardiotoxicity in the form of deadly abnormal rhythms in patients resulting from block of the major repolarizing potassium channel hERG (5) .
Unpredictable drug-induced arrhythmia has been estimated to affect pharmaceuticals from multiple drug classes (6) , with an estimated 3% of all prescription drugs worldwide harboring pro-arrhythmic side effects (7) . The problem has even plagued drugs intended to treat arrhythmias, with drugs from nearly all antiarrhythmic drug classes being linked to drug induced arrhythmia (8, 9) . Indeed, cardiotoxicity is one of the leading causes of drug attrition (10) , and accounts for 22-28% of US post-marketing drug withdrawal (11) .
Experimental studies alone cannot provide the necessary detailed structural information on drug interaction with ion channels. For instance, liquid chromatography with mass spectrometry can elucidate pharmacokinetic information (12, 13) , mutagenesis studies and voltage patch-clamp techniques can tentatively identify specific residues involved in drugchannel interactions (14) (15) (16) . Experimental techniques for determining high-resolution structures of drug-channel complexes at the atomic scale have their own limitations such as system size (NMR), bound state stability (X-ray) and resolution (cryogenic electron microscopy (cryo-EM) (17, 18) . The most important limitation for understanding drugprotein interactions, however, is the static nature of information provided by a single reported structure. It is well-established that the dynamic adaptation of the binding pocket in a protein receptor with bound drug, and protein dynamics itself, are central for understanding high-affinity and specificity of protein-ligand recognition (19) . Another important limitation in using a single receptor structure determined by NMR, X-Ray or cryo-EM techniques is related to an apparent need to sample all relevant conformational states for substrate and receptor itself and assigning their Boltzmann weights accurately (20) .
The availability of high-resolution structures of ion channels and robust computational modeling tools now make it possible to predict the impact of a drug molecule on the emergent electrical activity in the heart. Indeed, the structures of multiple ion channels at atomistic resolution have been determined in recent years via X-ray crystallography and cryo-EM (21, 22) . Significantly, a structure of the hERG channel in a putative open state was recently determined at a 3.8 Å resolution by cryo-EM (23) and was used in this study. The advances in molecular modeling and simulation methodology (24) and availability of powerful and efficient high-performance computing resources (25, 26) have made rigorous atomic-resolution investigation of ion channel function (27) , and ion channel -drug interactions (28) now feasible .
In this study, we show that it is possible to predict drug-channel kinetics from atomicresolution simulations, and hence begin to solve problem of preclinical drug cardiac safety screening in silico. Our current work expands upon our recent investigations (29) (30) (31) (32) (33) (34) (35) into drug and ion channel model development, and drug-channel binding using all-atom MD simulations. For instance, we recently developed and validated atomistic force field models of charged and neutral forms of the local anesthetic and anti-arrhythmic drug lidocaine and determined its preferred binding modalities and pathways in the cardiac voltage-gated sodium (NaV) channel using multi-microsecond long unbiased MD simulations, providing good agreement with available experimental electrophysiology data as well as new structural predictions (35) . In another recent work, we developed force field models of the hERG-blocking drug sotalol, which has high pro-arrhythmia proclivity, and studied its lipid membrane partitioning using both unbiased and enhanced sampling MD simulations, obtaining reasonably accurate energetics and kinetics of drug -lipid bilayer interactions (34) .
To develop our multi-scale prototype methodology, we focus here on another potent hERG blocker dofetilide (36) , which has a high proarrhythmic risk and has been extensively studied experimentally (37) (38) (39) . Many drugs like dofetilide and sotalol are weak bases, and therefore exist in equilibrium between ionized and neutral fractions in aqueous solution at physiological pH of 7.2. Both ionized and neutral drug forms are capable of accessing the hERG channel pore through an intracellular aqueous, but the neutral form is potentially capable of interacting with the channel by passage through lipid-facing fenestrations, as was proposed over 40 years ago (40) , suggested by recent channel structures (41, 42) and supported by our local anesthetic -NaV channel atomistic simulations (30, 35) .
In an earlier study (33) , we used preliminary dofetilide force field models and homology models of the hERG pore domain, based on then-available KV1.2/2.1 and KcsA structures (29) , to study effect of pH on the channel -drug interactions. We have recently integrated our atomistic simulation results using these models into multi-scale functional modeling of hormone effects on arrhythmogenesis induced by hERG mutations or drug channel block (32) . In another study, we used MD simulation results to gain insight into possible molecular mechanisms of flecainide action in treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) via multi-scale functional modeling (31) . However, in both cases such integration was limited by qualitative information about drug -lipid membrane (31) or drug / hormone -channel interactions (32), which was not directly used to parameterize functional models.
Furthermore, the published structure of the putatively open-state for the hERG channel (23) has challenged many of the previously-proposed modes of drug binding. The commonly accepted idea emphasized the importance of a wide and easily accessible intra-cavitary site provided a combination of amphipathic-to-polar (pore-helix residues) and hydrophobicaromatic moieties (S6 helix). Therefore, the intra-cavitary binding site provides a highaffinity/low-specificity binding pocket targeted by a broad panel of pharmaceutics ranging from anti-inflammatory to anti-convulsants and anti-arrhythmic drugs (43, 44) . In striking contrast, the high-resolution cryo-EM structure of the hERG intra-cellular cavity shows a very constricted space with an obvious hydrophobic character defined by the positions of S6 helix Y652 and F656 residues (23) . Here, we utilized this hERG channel structure to develop an atomic-scale model of hERG in an open conducting state, supported by our multimicrosecond-long MD simulations under applied voltage. Optimized structural atomistic models of charged and neutral dofetilide, compatible with biomolecular CHARMM force fields (45) , were developed and validated using lipid membrane partitioning molecular dynamics (MD) simulations. Then, we used multi-microsecond-long unbiased MD simulations to identify potential drug binding sites, entry and egress pathways. Finally, we used biased, one-dimensional umbrella sampling (US) MD simulations (46) to estimate binding affinities and association/dissociation rates (kon/koff) of charged and neutral dofetilide with open state hERG. These data are then used to inform functional scale models for predicting drug pro-arrhythmia risks, as described in the companion paper (47) .
The combination of computational modeling and simulation tools used in this study was optimized to allow for robust and accurate development and validation of atomistic in silico models of the channel-drug interactions. This approach allowed us to obtain quantitative estimates of state-dependent drug -channel binding affinities and rates, and then to directly utilize these quantities as parameters in our functional kinetic model of hERG -dofetilide interactions, as described in the companion paper (47) . This provides a novel link between our atomistic and functional kinetic models of in silico safety pharmacology and allows for prediction of a drug pro-arrhythmia proclivity based on its chemical structure -all the way from the atom to the rhythm.
Results
The goal of this study was to develop an accurate and robust quantitative atomic-scale model of the hERG channel -dofetilide interactions for a particular channel conformational state taking into account different drug ionization states and their channel binding pathways, as outlined in Figure 1A . To accomplish this goal, we developed and validated atomistic force field models of dofetilide in both charged and neutral ionization states (red and green hexagons in Figure 1A) . We then developed and validated an atomistic structural model of the hERG channel in an open conducting state based on the recent cryo-EM structure, shown schematically in Figure 1A . Next, we employed a variety of unbiased and enhanced sampling all-atom MD techniques to probe atomic scale mechanisms of dofetilide interaction with the hERG open channel. We utilized computed energetic and dynamic quantities to determine dofetilide ingress and egress rates to be used as parameters in functional protein-scale channel -drug model (outlined in Figure 1B ) and subsequent cell-and tissue-scale simulations discussed in the companion paper (47) .
Dofetilide Models and Membrane Interactions
Dofetilide has a basic (protonatable) tertiary amine group and two acidic sulfonamide groups with estimated aqueous pKa values of of 7.0, 9.0 and 9.6, respectively,(48) and therefore at physiological pH of 7.2 exists in equilibrium between neutral (Dofetilide(0) or DOFN) and cationic, i.e. positively charged (Dofetilide(+) or DOFC) dominant drug ionization forms (Figure 2A) , which have different polarities, lipophilicities and lipid membrane permeabilities. This was demonstrated in our previous study on the example of another hERG blocking drug sotalol, which has similar functional groups and can also exist in cationic and neutral forms (34) . Moreover, neutral and charged forms of a drug likely have different affinities for their protein targets, which was demonstrated in a recent study using hERG homology models and preliminary empirical force field models of dofetilide (33) . Hence, for this study, we have developed and validated structural models for charged and neutral forms of dofetilide, compatible with biomolecular all-atom CHARMM force fields (see SI Methods).
Our optimized DOFN and DOFC all-atom force field models are in good agreement with high-level quantum mechanical (QM) gas-phase molecular geometries, torsional energy profiles and interactions with water (see SI Tables S1-S3, Figures S1-S2 and discussion therein).
The derived parameters were validated by performing umbrella sampling MD simulations of DOFC and DOFN partitioning across a hydrated 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) lipid bilayer. From these simulations, the drug water -membrane distribution coefficient log D (derived using Eq. 2), can be compared with experimental counterparts, as we have done previously (34) . Moreover, drug-membrane interactions are crucial for understanding drug pharmacological properties, as cell membrane localization and permeation rates mediate the mechanism by which a drug affects its targets (34) .
The results shown in Figure 2B demonstrate that there are substantial membrane perturbations as cationic dofetilide, DOFC, moves towards the membrane center, whereas this was not observed for the neutral species, DOFN. Therefore, it is not unexpected that the energetic barrier for DOFC crossing the membrane is high (∆G= 15.8± 0.1 kcal/mol), and it is substantially lower (∆G= 6.0± 1.8 kcal/mol) for DOFN ( Figure 2C) . Moreover, while the neutral form of the drug has interfacial binding wells of -1.7± 0.7 kcal/mol at |z|=14 Å, the charged one does not bind at the water-membrane interface at all ( Figure 2C) . A membrane crossing barrier almost 2.6 times higher for DOFC compared to DOFN indicates much faster rate of crossing for the latter, whereas interfacial binding of the neutral form signifies that it can accumulate in that region. Based on free energy differences of two forms, we computed how drug pKa decreases as it moves across the membrane indicating its drastic deprotonation in the membrane interior (see Figure 2C and SI Figure S4C ). The free energy profiles in Figure 2C and Eq. 2 were used to compute the water-membrane distribution coefficient, logD = 0.32 at pH 7.2, which agrees reasonably well with experimental values of 0.84, 0.98 derived from water-octanol (49, 50) and 2.08 from water --Immobilized Artificial Membrane (IAM) (51) partitioning experiments.
Since we determined that DOFN accumulates at the water-membrane interface, we primarily expected it to be largely membrane-bound, contrary to its cationic counterpart DOFC. Indeed, our ~2.5 s long unbiased MD simulations demonstrate that the neutral form of the drug quickly (in <200ns) embeds into the membrane, while DOFC remains predominantly in aqueous solution (see SI Figure S11A ). These results indicated that DOFN could potentially access hERG through a hydrophobic pathway, but that the charged form will only enter through the aqueous pathway (52) . Moreover, due to a substantially smaller energetic barrier ( Figure 2C ), we expect much faster membrane translocation of DOFN. We also computed the diffusion coefficient, ( ), profiles across the POPC membrane for both forms of the drug, with values in the bulk water, W, of ~6 x10 -6 cm 2 /s for DOFC and ~7 x10 -6 cm 2 /s for DOFN, each attenuating to M <0.5 x10 -6 cm 2 /s at the membrane center ( Figure 2D and Table 1 ). Such an order of magnitude drop in the diffusion in the membrane interior was observed in our previous studies for ions and other drugs as well (30, 34, 53) . Based on these data, we estimated the membrane translocation rate of neutral dofetilide (see SI Methods) as 7.96 ± 1.37 ms -1 . For a charged drug, its membrane crossing rate is expected to be 3-4 orders of magnitude smaller than that for the neutral one and thus is not expected to make a significant contribution to dofetilide membrane translocation.
Open Conducting hERG Model
A crucial component of this work is a structural atomistic model of the hERG channel in a well-characterized, stable conformational state. Here we sought to develop an open, conducting model of the hERG based on the published cryo-EM structure (33) . This was achieved by rebuilding missing loop residues using Rosetta (see SI Methods) thus constructing a complete model of the hERG pore domain (PD) and voltage sensing domains (VSD), and tested the ability of this channel model to conduct K + ions in MD simulations.
After an extended stage system equilibration (see SI Table S4 ), we performed a ~1 s-long unbiased MD simulation, which revealed that the PD remained open with a pore radius of ~4 Å near activation gate, well hydrated and deviating from the initial structure by less than 3 Å (SI Figure S5 ). As expected, we did not observe ion conduction events in this simulation running at zero voltage.
However, we observed multiple K + ion conduction events during an unrestrained, multi-s MD simulation with an electric potential of 750 mV (positive inside) continuously applied along the z axis of the system, corresponding to the membrane normal, as shown in Figure   3 . A representative molecular snapshot of this open conducting hERG model is shown in Figure 3A .
The pore is open and solvent-accessible, while ions within the selectivity filter have adopted the canonical positions in an alternating "water-ion-water" orientation with ions at sites S1, S3 and cavity. Several frames from a representative conduction event of a K + ion (brown ball) across the selectivity filter are shown in Figure 3B , with other ions also colored to match traces from Figure 3C . Ten conduction events through the channel were observed in ~5 s total simulation time (see Figure S6A) , seven of which occurred within a 300 ns timespan, shown in Figure 3C . The ion SF transitions that facilitate conduction depicted by the brown ion are mediated by both water-mediated or "soft" (t = 478 ns) and direct or "hard" (t = 490 ns) knock-on events. K + conduction ceases after 1.75 μs, coinciding with a marked reduction in the channel pore diameter and consequently pore dehydration (SI Figures S6A and S7C) .
As a control, we also simulated the conduction of the KV1.2/2.1 paddle chimera (depicted in Figure 3D ), well-studied previously (54, 55) , under the same simulated conditions (750 mV applied voltage and 0.15 M KCl concentration). Our results indicated that the KV1.2/2.1 channel can also conduct multiple K + ions during ~5 s long simulations (one such event is depicted in Figure 3E ) and notably does not undergo hydrophobic pore collapse as in hERG (SI Figures S6B and S8C ). We observed 9 conduction events within an initial ~225 ns timespan ( Figure 3F ); ~70% more per unit time than in hERG conduction runs.
Interestingly, this difference is in line with hERG and KV1.2 single-channel conductances observed experimentally (12.1-13.5 pS for hERG (56, 57 ) and 14-18 pS for KV1.2 (58)), although the small number of such events was not sufficient to draw any quantitative conclusions.
Moreover, we also observed long refractory periods in both hERG and the KV1. Figures S9B and S10C) . This mutant is known to facilitate channel inactivation (59) , and thus such pinching could potentially be related to C-type inactivation, although simulation time scales are drastically smaller. Importantly, absence of conduction events for this hERG mutant indicates that even at high voltages used in our simulations we can distinguish between conducting and non-conducting channel states.
Dofetilide Binding Pathways
Having developed dofetilide force field models and validated that our hERG open-state model remains open for at least 1 s and can conduct K + ions during that time, we sought to identify key drug-protein interaction pathways. To do this, we used so called drug "flooding" simulations, as in our previous studies (30, 35) , where multi-s-long unbiased MD runs were performed starting from a system with multiple dofetilide molecules placed in the aqueous solution around hERG, embedded in a POPC bilayer. For each system, we applied 25 mM aqueous concentration of the drug (corresponding to 20 dofetilide molecules) and ran simulations for 2.5 μs. The final systems are shown in Figure 4A&B for DOFN and DOFC, respectively.
We observed that within first 500 ns of the simulation, most neutral drug becomes either embedded in the membrane or interacts with the protein (mostly at the intracellular side), thus reducing an effective aqueous concentration to less than 2 mM on average, while most DOFC molecules remain in aqueous solution transiently interacting with water-exposed hERG residues (See Figure 4A&B and SI Figure S11A ). In these simulations we have not encountered DOFN or DOFC translocation into the channel pore via a lipophilic pathway, observed in our previous local anesthetic -NaV channel simulations (30, 35) . However, for both DOFN and DOFC, we observed one spontaneous drug diffusion into the channel pore through the open intracellular gate after ~35 ns and ~244 ns, respectively (Figures 5A&B).
Once there, both forms remained bound for the duration of the simulation interacting, with S6 helix residues lining the pore, in particular, F656 and Y652, canonical hERG binding residues for dofetilide and most other hERG blocking drugs (60) (61) (62) . In fact, mutation of these residues greatly reduces dofetilide hERG binding affinity, with Y652A mutations, for example, diminishing block by more than 50-fold (63) 
Energetics and Kinetics of Dofetilide Binding to hERG
Our drug flooding simulations demonstrated that both DOFC and DOFN likely access hERG pore through the aqueous intracellular gate. However, since we only observed singular drug ingress events and no instances of egress in each case, we were unable to quantitatively estimate energetics and kinetics of drug binding from these runs. Therefore, US MD simulations for drug -channel interactions were employed to compute these quantities along the channel pore.
A crucial prerequisite for US MD simulations is the generation of initial structures. Since dofetilide is a long and flexible molecule, sampling its re-orientation and conformational transitions in the narrow hERG channel pore is an extremely challenging task, as the results of US MD simulations can be greatly influenced by the initial drug orientation and conformation. To minimize this initial bias, and at the same time, make the initial system generation robust, we developed the strategy depicted in Figure 6 . We employed steered molecular dynamics (SMD) to pull a drug molecule at a constant rate of 0.5 Å per ns from bulk aqueous solution (z=-50 Å) to the bottom of the SF (z=-5 Å) in five independent simulations, starting from different initial drug orientations. Since the optimal value for a pulling rate is known to be system specific (65) we chose one to allow for some drug relaxation within the channel pore. To seed our US MD simulations, we then randomly chose a frame from each of those 5 runs for the corresponding z position (Figure 6B&C) , such that no two adjacent US windows were from the same pulling run. In all pulling and US MD runs we had weak harmonic restraints on the channel pore domain C and SF backbone atoms to eliminate channel transition to a different conformational state (See SI Methods for additional details).
Potential of mean force (PMF) profiles computed from our US MD trajectories using the channel pore axis as the reaction coordinate allowed us to estimate the free energies of drug binding, ∆Gpore, and compute (using Eq.3) the dissociation constants (KDx) of dofetilide charged and neutral forms to the hERG channel in the open state. The results are summarized in Table 1 , and in Figure 7A) . Importantly, for both DOFC and DOFN we observed that there are no free energy barriers for binding from bulk aqueous solution, which suggests that channel ingress kinetics (or "on" rate, kon) will be diffusion limited. In addition, since neutral dofetilide binds more favorably in the channel pore than its charged counterpart, we expect a strong downward shift in the drug pKa, around the binding site (z  -20 to -15 Å) as was observed in the membrane interior (cf. SI Figures S13B
and S4B).
The equilibrium dissociation constant KDx for DOFN and DOFC were computed to be 0.16 M and 65.09 M, respectively ( Table 1) . Taking into account the relative fractions of charged (38%) and neutral (62%) dominant drug ionization forms at pH 7.2, using its basic amine literature pK a value of 7.0 (48), the overall K D is estimated (using Eq. 4) to be ~25.3 M, which agrees favorably with IC50 values (3.5 M, 10 M, 11 M) measured in electrophysiology experiments involving non-inactivating mutants of the channel or pulsing conditions disfavoring inactivated state (37, 57, 66 The topologies of the binding pockets for the neutral and charged forms of dofetilide in representative poses are shown in Figure 7B&C , respectively. DOFN binds with one end pointing up toward polar residues in the SF, stabilized by interactions near the its base (S624) as well as a cluster of residues from S6 helix including S660, Y652 and F656 from multiple chains (Figure 7B ), all residues that have been implicated in drug binding (62) . One of the sulfonamide oxygens formed hydrogen bonds with S624, and the other sulfonamide group is hydrogen bonded to S660 ( Figure 7B ). These interacting residues are similar to ones sampled in drug "flooding" simulations discussed above. However, the drug conformation is different -extended in "flooding" simulations and bent in US MD runs (cf. Figure 7B and Figure 5A ). One reason for this difference might be that in the former, the S6 pore helices were permitted to remain flexible, and adopt more constricted conformations.
Whereas in US simulations we weakly restrained the S6 helix backbone to ensure a consistent conformational channel state, in which the pore cavity remains slightly more widened than in unbiased MD runs. In both cases, however, polar methanesulfonamide termini are stabilized by hydrogen bonding interactions with S624 and S660 residues.
Interestingly, the S660 residue is known to be important for binding other bulky drugs like cisapride, terfenadine and ibutilide (69) DOFC was observed to bind below the Y652 ring at z=-20 Å and is also coordinated by hydrophobic residues F656 and Y652 from multiple chains, with both terminal methanesulfonamide groups coordinated via hydrogen bonds with S660 residues (near the intracellular ends of S6 helices) from two chains (see Figure 7C) . In other words, both ends of the molecule point down toward the bulk solvent, whereas its cationic ammonium group in the middle points up towards the SF and forms a hydrogen bond with Y652. Such drug conformation is fairly similar to one of those adopted by DOFC in drug "flooding" simulations (see Figure 5) .
To investigate the stability of the drug binding poses observed in US MD simulations, we performed 1 μs long unbiased simulations, starting with the end frame of the US MD runs at z=-15 Å for DOFN and z=-20 Å for DOFC, in their putative binding sites (see Figure 8) . DOFN remained bound in the pore and kept its bent conformation ( Figure 8A&C) . However, it tumbled with respect to the z axis (from ~20 to 100° and back), and its z position fluctuated from -15 to -22 Å (Figure 8A&B ), corresponding to a shallow trough at the US MD derived free energy profile ( Figure 7A ). An extended DOFN conformation, observed in our drug "flooding" MD runs, was not observed in these simulations which likely indicates existence of multiple stable binding poses with slow interconversion. Interestingly, for DOFC we observed several transient drug egress events for tens of ns, followed by its re-entry ( Figure   8A ). This was accompanied by drug tumbling with respect to the z axis (from ~60 to ~160° and back, see Figure 8B ) and more importantly, its adoption of an extended conformation after ~400 ns of the simulation (Figure 8C&D ). This binding pose resembles one from DOFN "flooding" simulation ( Figure 5A ) but was observed in here in our DOFC stability test run.
As for DOFN, this likely indicates existence of multiple low-energy binding poses separated by substantial barriers, precluding rapid interconversion.
We also computed the z-dependent diffusion profiles into the hERG pore for both drug forms ( Figure 7A ). Diffusion coefficients in the bulk aqueous solution, W, are ~6 x10 -6 cm 2 /s (at z = -50 Å) for both cationic and neutral dofetilide. They attenuate significantly to pore of 0.11 or 0.15 x10 -6 cm 2 /s for DOFN and DOFC, respectively (see Table 1 ), near the drug binding sites (i.e. at z  -15 or -20 Å for DOFN and DOFC). Comparing the diffusion coefficient profiles for drugs in the channel pore and membrane interior (see Figure 2D) , we see similar qualitative behavior -that their diffusion significantly slows down (by an order of magnitude or more) compared to bulk aqueous solution, due to a more viscous medium (in the membrane interior) or constricted space (in the channel pore). Interestingly, such reduction is more pronounced in the hERG pore (40-fold reduction) compared to the membrane interior (20-fold reduction).
Using the free energy (PMF) and diffusion coefficient profiles in Figure 7A along with Eqs. 5 and 6 we computed drug ingress rates (kon=666 μM -1 s -1 for DOFN, and kon=534 μM -1 s -1 for DOFC) and egress rates (koff=106 s -1 for DOFN and koff=3.47 x10 4 s -1 for DOFC) for open hERG pore, summarized in Table 1 , which we will be using directly in our multi-scale computational model for predictive cardiac safety pharmacology, discussed in our companion paper (47) . Since drug -channel association or ingress rates (kon) are diffusioncontrolled, our estimates are similar for charged and neutral forms of the drug. The drugchannel dissociation or egress rates, koff, on the other hand, are directly proportional to drug dissociation constants, KDx. Therefore, stronger DOFN binding leads to a ~65-fold reduction in its egress rate compared to DOFC. This also correlates with the results of our 1 μs long unbiased MD simulations of drug binding, which demonstrated partial drug unbinding in DOFC but not DOFN run.
We can also compare drug ingress rates at maximum physiological dofetilide plasma concentration Cmax of ~6.16 nM (see the companion paper (47)), x Cmax  kon (where x is DOFN or DOFC fraction at pH = 7.2), equal to 2.5 and 1.2 s -1 for DOFC and DOFN, respectively, with that for DOFN membrane translocation, 7.96 ms -1 or 7,960 s -1 . The latter is over 3 orders of magnitude faster indicating that kinetics associated with open hERG -dofetilide interaction will be a rate-determining step and should definitely be taken into account in our functional models, discussed in our companion paper (47) .
Discussion
In this study we take the initial steps towards a multi-scale modeling framework to predict the effect of dofetilide on the heart starting from atomic scale structural models of hERGdrug interactions. State-specific drug -channel ingress and egress rates computed from the atomic scale MD simulations were used to parameterize a functional kinetic channel model that captures the dynamical interactions of dofetilide with hERG (see Figure 1B) in the second part of this study (see the companion paper (47)). Our functional kinetic proteinscale model has been integrated into predictive functional kinetic models at the cell and tissue scales to expose fundamental arrhythmia vulnerability mechanisms and complex interactions underlying emergent behaviors.
Typically, experimental biophysical and biochemical data are used to predict parameters associated with drug effects on protein targets for functional multi-scale models (70) .
However, many important variables such as a particular drug ionization and channel conformation are difficult to control experimentally (71, 72) . Atomistic MD simulations are ideally suited to address this challenging problem by providing necessary spatial and temporal resolutions to compute state-dependent drug binding affinities and rates.
In this study we developed and validated models of charged (cationic) and neutral forms of dofetilide, compatible with biomolecular CHARMM force fields, that were optimized using high-level QM data as a reference. Then we performed membrane partitioning MD simulations, revealing that only the neutral form of the drug is expected to localize at watermembrane interface, with a relatively fast translocation rate of ~8 ms -1 . The charged form is not expected to contribute to drug membrane translocation due to ~4 times larger barrier.
Our computed water -membrane distribution coefficient logDMW of 0.32 at pH 7.2 is in reasonable agreement with experimental logD values for water-octanol of 0.84 -0.98 (49, 50) and for water -artificial supported membrane of 2.08 (49), somewhat underestimated compared to the latter. The discrepancy does not necessarily indicate model deficiencies, and can be related to experimental methodology or data interpretation (73) . There is also uncertainty in dofetilide pKa value (48, 67, 68) , which would affect computed logDMW as well as composite drug-channel composite Kd value (see below), but not individual estimates for charged and neutral drug forms, used in our multi-scale functional model.
We also developed and validated a model of hERG in the open conducting conformation based on the recently published cryo-EM structure of hERG (33) . The model demonstrated multiple K + conduction events in ~0.3 s span of simulations under a strong +750 mV voltage, which was previously used to facilitate ion conduction for KcsA and KV1.2/2.1 channels (54, 74) . Qualitatively similar conduction behavior was observed in our reference KV1.2/2.1 channel simulation at the same simulation conditions. Importantly, we demonstrated that our hERG model likely represents an open conducting state, and that its alteration, via inactivation-accelerating S641A mutations, can render it non-conductive.
Having developed and validated atomistic models of dofetilide and hERG, we started studying their interactions via all-atom MD runs. First, we performed so called multi- To obtain dofetilide free energy and diffusion coefficient profiles, we performed umbrella sampling MD simulations of charged and neutral dofetilide binding to hERG pore via the intracellular gate (see Figure 7A) . We observed stronger binding of neutral dofetilide deep inside the channel pore and close to the bottom of the SF compared to charged dofetilide, which was bound less tightly further down the channel pore. This suggests possibility of drug deprotonation inside the pore, although not as drastic as in the membrane interior.
Interestingly, we observed that drug diffusion is slowed down by an order of magnitude in both channel pore and membrane interior, but more though in the former due to constricted environment (Figures 7A and 2D) . Based on the free energy and diffusion data we computed drug dissociation constants as well as drug ingress (entry) and egress (exit) rates (see Table 1 ), which were incorporated into our multi-scale functional model, as discussed in the companion paper (47) . As expected, the diffusion-controlled drug ingress rates (kon) are similar for both charged and neutral dofetilide species, whereas egress rate (koff), dependent on drug binding affinity, is almost 2 orders of magnitude lower for neutral dofetilide. Importantly, dofetilide-hERG ingress rate values at maximum physiological plasma concentration are over 3 orders of magnitude smaller than our estimate for neutral dofetilide membrane permeation rate, indicating that drug-channel association is likely to be a rate-limiting step for the entire drug/channel/membrane system and should be incorporated into our functional kinetic channel model (see Figure 1B and companion paper (47)). Our computed composite Kd value estimates of 25 -56 M, taking into account neutral and charged dofetilide contributions at pH 7.2 and pKa of 7.0 -8.0 (48, 67, 68) , are in reasonably good agreement with experimental IC50 estimates (3.5 -11 M) of dofetilide binding to non-inactivated channel state (37, 57, 66) . This indicates that our atomistic channel -drug model is likely to be accurate enough to be used in providing parameters for our predictive multi-scale kinetic models of cardiac safety pharmacology.
Notably, experimental data suggest that dofetilide binds considerably stronger to inactivated hERG state, with IC50 in the low nanomolar range (36, (75) (76) (77) (78) . In this study we considered drug binding only to an open conducting channel state, for which we have structural data. In order to include dofetilide binding to the inactivated state into our functional model for this prototype study, we used the experimental ratio of binding affinities to these two states (see the companion paper (47)). However, future model development will necessitate a structural model of the channel inactivated state (see SI for a more detailed description).
The atomistic molecular modeling and simulation protocol we have developed in this work was utilized for estimating multi-scale functional model parameters as described in the companion paper (47) . It can be used, for example, as a structural predictor of experimental electrophysiology channel inhibition or drug radioligand binding assays. It is modulatory and can be easily modified or amended as needed, and steps can be potentially automated using computational workflows, as was done recently for our functional models (79) . We are working to expand these studies to other hERG blocking drugs with different proarrhythmia proclivities and also to consider multi-channel block as well, as emphasized in CiPA initiative (80, 81) . This study represents a crucial step towards our ultimate goal to provide and thoroughly test a transferrable in silico protocol for accurate and efficient prediction of the cardiotoxicity of any drug or drug candidate based on their chemical structures, which will help decrease costs associated with drug development and lead to development of safer drugs and save human lives. Ion conduction and drug flooding channel simulations: hERG systems were equilibrated with NAMD for 90 ns using gradually reduced restraint regime (see SI Methods and SI Table   S4 ) and then simulated on the Anton 2 supercomputer for 2.5 -5 μs. KV1.2/2.1 systems were equilibrated with NAMD for 50 ns before 5 μs Anton 2 production runs. Ion conduction simulations contained no drug and had +750mV transmembrane voltage via applied electric field across the simulation box z axis and were run using the NVT ensemble. Drug flooding simulations were set up such that there was a 25 mM initial concentration of dofetilide randomly distributed in aqueous solution and were run in the NPT ensemble. 
Materials and Methods
Drug
Umbrella sampling (US
where pKa is acid dissociation constant of dofetilide. Drug membrane translocation rate was estimated using Kramer's rate equation, as was done previously (30).
Drug -channel binding thermodynamics and kinetics:
The effective equilibrium dissociation constants Kx of charged (x=1) and neutral (x=0) drug forms were computed from PMFs of dofetilide -hERG pore binding US MD simulations as done previously (33):
where R is the restraint radius of the drug that encompasses the width of the channel pore (10Å), kB is the Boltzmann constant, T is the temperature in Kelvin, and Wx(z) is the potential of mean force (PMF) along the reaction coordinate from a point in the intracellular bulk aqueous solution (zout) to a point below channel SF (zbind). The composite KD value to be compared with available experimental data (see Table 1 Water-membrane partitioning coefficients (logPx) and distribution coefficient (logDMW) at pH=7.2 as well as diffusion coefficients in bulk water ( W) and membrane center ( M) were computed from 1D umbrella sampling MD simulations for charged (DOFC) and neutral (DOFN) dofetilide translocation across a POPC membrane. They were compared to experimental water-octanol distribution coefficients (logDOW) from references a (50) and b (49) and water -immobilized artificial membrane (IAM) high-performance liquid chromatography (HPLC) distribution coefficient (logDMW) from reference (50) . Free energies (∆Gpore) and diffusion coefficients ( pore) of DOFC and DOFN at the binding site in the channel pore as well as corresponding dissociation constants (Kx), association (kon) and dissociation (koff) rates were computed from 1D umbrella sampling simulations along the channel pore. Net (composite) dofetilide dissociation constant (KD) at pH=7.2 was compared to the experimental half maximal inhibitory concentrations (IC50) of the drug to noninactivated hERG from references d (66) . e (57) . f (37) . See text for more details. 
